IBAT Inhibitors: Clinical Trial Results and Emerging Role in PBC

This keynote explores groundbreaking advancements in genetic cholestasis, emphasizing genomic tools and IBAT inhibitors such as maralixibat and odevixibat. Highlighting key clinical trials like ICONIC and PEDFIC, it addresses efficacy, minimal side effects, and regulatory successes. Emerging treatments for primary biliary cholangitis, including seladelpar and elafibranor, are discussed alongside personalized approaches. Concluding with future directions, the focus is on expanding therapeutic...